Loading...
http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.redefining-healthcaregk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-our-employeesgk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-our-principalsgk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-your-business-1gk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-your-businessgk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-your-healthgk-is-126.jpg

Scientific Events

Corporate Events

Trainings

Product Launches

CSR Events

Company News

A+ A A-

NEXPRAZOLE Launch In Sri Lanka on 18th March,2012

aPicture16 -_280x196Nexprazole (Esomeprazole), a proton pump inhibitor (PPI) manufactured by OBS for the treatment of acid-related diseases such as dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome, was launched in Sri Lanka on 18th March 2012.

The launch program was held in Colombo on a Jetliner (Sri Lanka Navy’s largest passenger craft that served as a life line between the North and East during the Humanitarian Operation). The event was heavily attended by over 250 participants from all across the country that included Key Opinion Leaders (KOLs) from relevant specialties like Gastroenterologists, Cardiologists, Neurologists, Physicians and General Practitioners.

This program provided an excellent opportunity for the OBS management to share their vision and aggressive future plans for expansion in Sri Lanka and at the same time to gain valuable feedback from the Key Opinion Leaders where to focus their future direction to best serve the welfare of the patients in Sri Lanka.

Click to view gallery

Copyrights © 2011-2014 All Rights Reserved OBS.